Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-cash Items (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Non-cash Items for 4 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 22.66% to $6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Dec 2025, up 22.66% year-over-year, with the annual reading at $6.1 million for FY2025, 22.66% up from the prior year.
  • Non-cash Items for Q4 2025 was $6.1 million at Century Therapeutics, down from $9.4 million in the prior quarter.
  • The five-year high for Non-cash Items was $38.4 million in Q1 2023, with the low at $227000.0 in Q4 2022.
  • Average Non-cash Items over 4 years is $12.9 million, with a median of $6.2 million recorded in 2025.
  • The sharpest move saw Non-cash Items skyrocketed 1634.8% in 2023, then crashed 88.44% in 2024.
  • Over 4 years, Non-cash Items stood at $227000.0 in 2022, then surged by 1634.8% to $3.9 million in 2023, then increased by 26.96% to $5.0 million in 2024, then grew by 22.66% to $6.1 million in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $6.1 million, $9.4 million, and $6.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.